CREON Dosing Strengths & Instructions

The CREON® dosage should be individualized and adjusted based on clinical symptoms, the degree of steatorrhea present, and the fat content of the diet.

Dosing Strengths (Dose by Lipase Units)

CREON 36,000 units
Lipase
114,000 units
Protease
180,000 units
Amylase
CREON 24,000 units
Lipase
76,000 units
Protease
120,000 units
Amylase
CREON 12,000 units
Lipase
38,000 units
Protease
60,000 units
Amylase
CREON 6,000 units
Lipase
19,000 units
Protease
30,000 units
Amylase
CREON 3,000 units
Lipase
9,500 units
Protease
15,000 units
Amylase

Capsules shown are not actual size and do not represent exact color shade.

CREON offers several dosing options. The 36,000 lipase dosing option may decrease capsules required for some patients who have higher lipase needs.

CREON is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.1

CREON dosing and administration instructions

  • CREON should always be taken with food. CREON should not be crushed or chewed.
  • If a CREON dose is missed, the next dose should be taken with the next meal. Doses should not be doubled.
  • Usually, half of the prescribed CREON dose for an individualized full meal should be given with each snack.
  • CREON dosage should be individualized and adjusted based on clinical symptoms, the degree of steatorrhea present, and the fat content of the diet.
  • Fibrosing colonopathy has been reported in patients with cystic fibrosis taking high-dose pancreatic enzyme replacement therapy. Exercise caution if CREON dose exceeds 2,500 lipase units per kg of body weight per meal (or greater than 10,000 lipase units per kg of body weight per day).
  • CREON is not interchangeable with any other pancrelipase product.

IMPORTANT SAFETY INFORMATION

  • Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment of cystic fibrosis patients. Exercise caution when doses of CREON exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day).
  • To avoid irritation of oral mucosa, care should be taken to ensure that CREON is not crushed, chewed, or retained in the mouth. CREON should always be taken with food.
  • Porcine-derived pancreatic enzyme products contain purines. Caution should be exercised when prescribing CREON to patients with gout, renal impairment, or hyperuricemia.
  • There is theoretical risk of viral transmission with all pancreatic enzyme products including CREON.
  • Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
  • Adverse reactions that occurred in at least 2 cystic fibrosis patients (greater than or equal to 4%) receiving CREON were vomiting, dizziness, and cough.
  • Adverse reactions that occurred in at least 1 chronic pancreatitis or pancreatectomy patient (greater than or equal to 4%) receiving CREON were hyperglycemia, hypoglycemia, abdominal pain, abnormal feces, flatulence, frequent bowel movements, and nasopharyngitis.
  • CREON is not interchangeable with any other pancrelipase product.

INDICATIONS

CREON® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

Reference:
  1. CREON [package insert].

OTHER TOPICS


Patient Support Program

CFCareForward offers nutritional, financial, and educational resources.


CREON MOA

See how CREON works.

CREON Co-pay Assistance

Make sure your patients receive the CREON co-pay card.